Novo Nordisk, the pharmaceutical company behind the popular Wegovy injection, has brought its oral weight-loss medication to UK pharmacies. The once-daily pill offers patients an alternative to the weekly injection that has dominated headlines in recent years.
The tablet version contains the same active ingredient as Wegovy's injection: semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. This drug works by slowing stomach emptying and signaling fullness to the brain, reducing appetite and food intake. Clinical trials show semaglutide helps people lose around 10-15% of their body weight when combined with lifestyle changes.
The pill differs from the injection in one critical way: dosing frequency. Patients take the tablet daily rather than once weekly, which appeals to people who prefer oral medication or fear needles. Both forms carry similar side effects, including nausea, vomiting, and gastrointestinal issues, particularly during the first weeks of treatment.
The medication requires a private prescription in the UK, meaning the National Health Service does not currently cover it. This restricts access to patients who can afford the cost. The NHS does prescribe semaglutide injections for eligible patients meeting specific criteria, primarily those with type 2 diabetes or significant obesity-related complications.
Semaglutide's rise has sparked both enthusiasm and concern. Weight-loss drugs address a real health challenge, as obesity increases risks for heart disease, type 2 diabetes, and certain cancers. Yet supply shortages have affected patients with diabetes who depend on the medication for blood sugar control. Celebrity adoption has also fueled demand beyond medical need.
For potential users, understanding realistic expectations matters. The pill works best alongside diet and exercise changes, not as a standalone solution. Weight typically returns within months of stopping the medication, so long-term